Clinical Research Directory
Browse clinical research sites, groups, and studies.
Long-term Safety and Efficacy Evaluation of IMG-007 in Participants With Moderate-to-Severe Atopic Dermatitis
Sponsor: Inmagene LLC
Summary
The purpose of this study is to evaluate the safety and efficacy of long-term treatment with IMG-007 in participants with moderate-to-severe atopic dermatitis (AD)
Official title: A Long-term Extension Study to Evaluate the Safety and Efficacy of Subcutaneous IMG-007 in Participants of a Previous IMG-007 Moderate-To-Severe Atopic Dermatitis Clinical Trial
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
400
Start Date
2026-06-05
Completion Date
2028-03
Last Updated
2026-07-29
Healthy Volunteers
No
Interventions
IMG-007
Participants will receive IMG-007 subcutaneously.
Locations (23)
Inmagene Site 1
Lancaster, California, United States
Inmagene Site 23
Los Angeles, California, United States
Inmagene Site 19
Ocala, Florida, United States
Inmagene Site 4
Tampa, Florida, United States
Inmagene Site 2
Rolling Meadows, Illinois, United States
Inmagene Site 6
Kew Gardens, New York, United States
Inmagene Site 21
New York, New York, United States
Inmagene Site 11
Woodbury, New York, United States
Inmagene Site 20
Charlotte, North Carolina, United States
Inmagene Site 10
Fargo, North Dakota, United States
Inmagene Site 9
Columbus, Ohio, United States
Inmagene Site 5
Mayfield Heights, Ohio, United States
Inmagene Site 3
Portland, Oregon, United States
Inmagene Site 12
Anderson, South Carolina, United States
Inmagene Site 8
Southlake, Texas, United States
Inmagene Site 7
Burien, Washington, United States
Inmagene Site 15
Surrey, British Columbia, Canada
Inmagene Site 22
Vancouver, British Columbia, Canada
Inmagene Site 17
Greater Sudbury, Ontario, Canada
Inmagene Site 13
Mississauga, Ontario, Canada
Inmagene Site 18
North Bay, Ontario, Canada
Inmagene Site 14
Montreal, Quebec, Canada
Inmagene Site 16
Saskatoon, Saskatchewan, Canada